Background Genetic factors are estimated to account for approximately 30–50% of the risk for developing Multiple sclerosis (MS). Distinct mitochondrial variants, impairments in the respiratory chain, and mitochondrial dysfunction have been reported in individuals affected by MS. Mitochondria and the endoplasmic reticul...
Celina Böse, Adriana Rehm, Zhi-Xiao Wu et al.· Frontiers in Neurology· 0 citations
B cell depleting therapies in multiple sclerosis (MS) have transformed disease management, yet the immunological mechanisms linking B cells to chronic compartmentalised CNS inflammation, the key pathological driver of disability accrual, remain poorly defined. Here, we leverage anti-CD20 therapy as an in vivo perturbat...
Redwan Farooq, Brian Cutler, M. Pisa et al.· Brain : a journal of neurolo...· 0 citations
The 2024 revisions of the McDonald criteria aim to facilitate an accurate and early diagnosis of MS potentially enabling earlier MS therapy initiation, however, the routine implementation requires an expansion of resources and expertise limiting the general applicability in the German healthcare system.
M. P. Wattjes, A. Bayas, Stefan Bittner et al.· Therapeutic Advances in Neur...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
